PCRX · Pacira BioSciences, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on PCRX. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About PCRX · Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Live Quote
HOLD (score +3) · 12-1 mom -4.6% · RSI 54.7 · above_200_only · -13.6% from high
Targets blend Wall Street consensus (6 analysts: low $23.00 / mean $29.67 / high $38.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.
Fails the concentration anti-signal gate (79% of sales routed through three wholesalers) and scores poorly across all rubric categories due to zero smart-money conviction, deteriorating earnings surprise history, thin margins, and lack of a near-term asymmetric catalyst.
Pacira is a specialty pharma focused on non-opioid pain management with three commercial products: EXPAREL (80% of revenue), ZILRETTA (OA knee), and iovera° (cryoanalgesia device). The investigation trigger cited insider cluster activity but Form 4 filings for the past several weeks returned zero results — a discrepancy worth flagging. The stock trades near its 52-week range at forward P/E ~6.3x, which is cheap relative to peers but explained by thin margins (ROIC low), heavy SG&A spend, and revenue concentration in three products from three wholesalers (~79%). An activist contest from DOMA Perpetual Capital Management (7.5% holder) at the June 2026 annual meeting produced mixed outcomes — management's board nominees won cleanly, but Say-on-Pay failed narrowly and the Stock Incentive Plan was rejected by stockholders, signaling governance friction without triggering a board change.